BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share

BIOMARIN PHARMACEUTICAL INC

BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.
BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.
Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.
Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.